Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: gabriele l. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
The use of microarray technologies in clinical oncology.
Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foà R, Belardelli FM. Gabriele L, et al. J Transl Med. 2006 Feb 7;4:8. doi: 10.1186/1479-5876-4-8. J Transl Med. 2006. PMID: 16464241 Free PMC article. No abstract available.
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.
Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L. Schiavoni G, et al. Among authors: gabriele l. Cancer Res. 2011 Feb 1;71(3):768-78. doi: 10.1158/0008-5472.CAN-10-2788. Epub 2010 Dec 13. Cancer Res. 2011. PMID: 21156650
A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells.
Mattei F, Schiavoni G, De Ninno A, Lucarini V, Sestili P, Sistigu A, Fragale A, Sanchez M, Spada M, Gerardino A, Belardelli F, Businaro L, Gabriele L. Mattei F, et al. Among authors: gabriele l. J Immunotoxicol. 2014 Oct;11(4):337-46. doi: 10.3109/1547691X.2014.891677. Epub 2014 Mar 6. J Immunotoxicol. 2014. PMID: 24597645
Consensus guidelines for the detection of immunogenic cell death.
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Kepp O, et al. Among authors: gabriele l. Oncoimmunology. 2014 Dec 13;3(9):e955691. doi: 10.4161/21624011.2014.955691. eCollection 2014 Oct. Oncoimmunology. 2014. PMID: 25941621 Free PMC article. Review.
Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A, Stellacci E, Romagnoli G, Licursi V, Parlato S, Canini I, Remedi G, Buoncervello M, Matarrese P, Pedace L, Ascione B, Pizzi S, Tartaglia M, D'Atri S, Presutti C, Capone I, Gabriele L. Fragale A, et al. Among authors: gabriele l. Int J Cancer. 2023 Sep 1;153(5):1080-1095. doi: 10.1002/ijc.34602. Epub 2023 Jun 9. Int J Cancer. 2023. PMID: 37293858
91 results